"Semaglutide has far-reaching benefits beyond what we initially imagined," Harlan Krumholz of the Yale School of Medicine said Friday at the European Society of Cardiology Conference 2024, as quoted by the BBC. "It's not just avoiding heart attacks. These are health promoters. It wouldn't surprise me that improving people's health this way actually slows down the aging process."
The studies were conducted as part of the Select trial in the US, which in all followed more than 17,600 people, 45 years of age and older, who were obese or overweight and had cardiovascular disease, but did not have diabetes. Over the course of more than three years, each of these subjects were given semaglutide or a placebo.
The results were stark. The patients who took semaglutide died at a 19 percent lower rate from all causes compared to the placebo group, the studies found, including from infections and cardiovascular issues. Deaths from COVID-19, for example, were reduced by 33 percent.
Semaglutide is a GLP-1 agonist, meaning it mimics the GLP-1 hormone that manages your body's production of insulin. This means that it's effective at managing blood sugar levels, but because the hormone affects your brain's perception of satiety, it can also be used to suppress your appetite and change the way your body processes food.
Collection
[
|
...
]